{"id":"doi:10.1007/s00406-016-0692-7","kind":"article","title":"Reduction of dopamine D 2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys","authors":["Hashimoto K","Kakiuchi T","Ohba H","Nishiyama S","Tsukada H"],"author_count":5,"year":2017,"published":"2016-04-18","venue":"European archives of psychiatry and clinical neuroscience","cited_by":105,"doi":"10.1007/s00406-016-0692-7","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1007/s00406-016-0692-7","archive_url":"https://space-kitty.com/papers/doi:10.1007/s00406-016-0692-7","updated":null,"pmid":"27091456","pmcid":"PMC5323469","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC5323469/pdf","abstract":"R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to esketamine (S-ketamine), since it might be free of psychotomimetic side effects. Using [ 11 C]raclopride and positron emission tomography (PET), we investigated whether esketamine and R-ketamine can affect dopamine D 2/3 receptor binding in the conscious monkey brain. A single infusion of esketamine (0.5 mg/kg), but not R-ketamine (0.5 mg/kg), caused a reduction of binding availability of dopamine D 2/3 receptor in the monkey striatum. This study suggests that unlike to R-ketamine, esketamine can cause dopamine release in the striatum, and that its release might be associated with psychotomimetic effects of esketamine.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Reduction of dopamine D 2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys\" by Hashimoto K, Kakiuchi T, Ohba H et al., https://doi.org/10.1007/s00406-016-0692-7, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}